Synthesis of68Ga-radiopharmaceuticals using both generator-derived and cyclotron-produced68Ga as exemplified by [68Ga]Ga-PSMA-11 for prostate cancer PET imaging

Melissa E. Rodnick, Carina Sollert, Daniela Stark, Mara Clark, Andrew Katsifis, Brian G. Hockley, D. Christian Parr, Jens Frigell, Bradford D. Henderson, Laura Bruton, Sean Preshlock, Monica Abghari-Gerst, Morand R. Piert, Michael J. Fulham, Stefan Eberl, Katherine Gagnon, Peter J. H. Scott

Published: 2022-03-03 DOI: 10.1038/s41596-021-00662-7

68Ga-radiopharmaceuticals

PSMA-11

PET imaging

prostate cancer

synthesis methods

AI 解读

Efficient and safe single-cell cloning of human pluripotent stem cells using the CEPT cocktail

Profiling native pulmonary basement membrane stiffness using atomic force microscopy

Genetic circuit design automation with Cello 2.0

Synthesis of siRNA nanoparticles to silence plaque-destabilizing gene in atherosclerotic lesional macrophages

Scalable dual-omics profiling with single-nucleus chromatin accessibility and mRNA expression sequencing 2 (SNARE-seq2)

A practical guide to scanning light-field microscopy with digital adaptive optics

Effective high-throughput isolation of fully human antibodies targeting infectious pathogens

Improved sampling and DNA extraction procedures for microbiome analysis in food-processing environments

MOF-derived nanoporous carbons with diverse tunable nanoarchitectures

Tutorial: a statistical genetics guide to identifying HLA alleles driving complex disease

查看全部

Sections

Figures

References

[68Ga]Ga-PSMA-11, a urea-based peptidomimetic, is a diagnostic radiopharmaceutical for positron emission tomography (PET) imaging that targets the prostate-specific membrane antigen (PSMA). The recent Food and Drug Administration approval of [68Ga]Ga-PSMA
Introduction
Materials
Procedure 1: production of [68Ga]Ga-PSMA-11 using generator-derived 68Ga
Procedure 2: production of [68Ga]Ga-PSMA-11 using cyclotron-produced 68Ga
Procedure 3: QC testing of [68Ga]Ga-PSMA-11
Troubleshooting
Timing
Anticipated results
References
ACKNOWLEDGMENTS
ACKNOWLEDGMENTS

Becker, K. V. et al. A review of accelerator-produced Ga-68 with solid targets. Curr. Radiopharm. http://doi.org/10.2174/1874471013666201224113651 (2020).
Svedjehed, J., Pärnaste, M. & Gagnon, K. Demystifying solid targets: simple and rapid distribution-scale production of [68Ga]GaCl3 and [68Ga]Ga-PSMA-11. Nucl. Med. Biol. http://doi.org/10.1016/j.nucmedbio.2021.10.002 (2022).
Hermann, K. et al. Radiotheranostics: a roadmap for future development. Lancet Oncol. 21, e146–e156 (2020).
Qaim, S. M. Theranostic radionuclides: recent advances in production methodologies. J. Radioanal. Nucl. Chem. 322, 1257–1266 (2019).
Kopka, K. A short history of transforming the diagnostic tracer PSMA-11 into the theranostic variant PSMA-617. Endocr. Abstr. 47, OC29 (2016).
Al-Nahas, A. et al. Gallium-68 PET: a new frontier in receptor cancer imaging. Anticancer Res 27, 4087–4094 (2007).
Decristoforo, C. Gallium-68—a new opportunity for PET available from a long shelf-life generator—automation and applications. Curr. Radiopharm. 5, 212–220 (2012).
Filippi, L. et al. Theranostic approaches in nuclear medicine: current status and future prospects. Expert Rev. Med. Dev. 17, 331–343 (2020).
Pencharz, D. et al. Theranostics in neuroendocrine tumours: somatostatin receptor imaging and therapy. Br. J. Radiol. 91, 20180108 (2018).
Werner, R. A. et al. The theranostic promise for neuroendocrine tumors in the late 2010s—where do we stand, where do we go? Theranostics 8, 6088–6100 (2018).
CancerNet. Prostate Cancer: Statistics http://www.cancer.net/cancer-types/prostate-cancer/statistics (accessed 27 April 2021).
Afshar-Oromieh, A. et al. PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur. J. Nucl. Med. Mol. Imaging 40, 486–495 (2013).
Abghari-Gerst, M. A comprehensive assessment of 68Ga-PSMA-11 PET in biochemically recurrent prostate cancer: results from a prospective multi-center study in 2005 patients. J. Nucl. Med. http://doi.org/10.2967/jnumed.121.262412 (2021).
Carlucci, G. 68Ga-PSMA-11 NDA approval: a novel and successful academic partnership. J. Nucl. Med. 62, 149–155 (2021).
Telix. FDA approves Telix’s prostate cancer imaging product, Illuccix® [press release]. http://telixpharma.com/news-media/fda-approves-telixs-prostate-cancer-imaging-product-illuccix/ (20 December 2021).
Stephens, K. FDA approves first commercially available PSMA PET imaging agent for prostate cancer. AXIS Imaging News http://www.proquest.com/docview/2533524558 (2021).
Lee, C. H. et al. The feasibility of 64Cu-PSMA I&T PET for prostate cancer. Cancer Biother. Radiopharm. http://doi.org/10.1089/cbr.2020.4189 (2021).
Jones, W. PSMA theranostics: review of the current status of PSMA-targeted imaging and radioligand therapy. Cancers 12, 1367 (2020).
Lenzo, N. et al. Review of gallium-68 PSMA PET/CT imaging in the management of prostate cancer. Diagnostics 8, 16 (2018).
Massat, M. B. Nuclear medicine prepares for greater 68Ga demand. Appl. Radiol. 50, 30–31 (2021).
Jackson, I. M. et al. Use of 55 PET radiotracers under approval of a Radioactive Drug Research Committee (RDRC). EJNMMI Radiopharm. Chem. 5, 24 (2020).
Rodnick, M. E. et al. Cyclotron-based production of 68Ga, [68Ga]GaCl3, and [68Ga]Ga-PSMA-11 from a liquid target. EJNMMI Radiopharm. Chem. 5, 25 (2020).
Do Carmon, S. J. C., Scott, P. J. H. & Alves, F. Production of radiometals in liquid targets. EJNMMI Radiopharm. Chem. 5, 2 (2020).
Gallium (68Ga) PSMA-11 injection. European Pharmacopoeia. 10, 5397–5398 (2021).
Cutler, C. S. & Minoshima S. Shortage of Germanium68/gallium68 generators in the United States http://s3.amazonaws.com/rdcms-snmmi/files/production/public/Ga68%20shortage%20letter.pdf (Society of Nuclear Medicine and Molecular Imaging, 2018).
Soto-Montenegro, M. L. et al. Meningiomas: a comparative study of 68Ga-DOTATOC, 68Ga-DOTANOC and 68Ga-DOTATATE for molecular imaging in mice. PLoS ONE 9, e111624 (2014).
Martin, R. et al. Cationic eluate pretreatment for automated synthesis of [68Ga]CPCR4.2. Nucl. Med. Biol. 41, 84–89 (2014).
Society of Nuclear Medicine and Molecular Imaging. FDA approves cyclotron-produced Ga-68 DOTATOC for neuroendocrine tumors [press release]. www.snmmi.org/NewsPublications/NewsDetail.aspx?ItemNumber=34801 (2020).
Gallium (68Ga) Chloride (accelerator produced) solution for radiolabelling. European Pharmacopoeia. 10, 4864–4865 (2020).

Synthesis of68Ga-radiopharmaceuticals using both generator-derived and cyclotron-produced68Ga as exemplified by [68Ga]Ga-PSMA-11 for prostate cancer PET imaging

Supplementary information

Reporting Summary

推荐阅读